Telisotuzumab Adizutecan

Phase 3Small molecule

Telisotuzumab Adizutecan is one of 176 small molecule programs targeting Pancreatic Ductal Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

175

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic Ductal AdenocarcinomaActive, not recruiting

Esophageal AdenocarcinomaActive, not recruiting

Metastatic Colorectal CancerRecruiting

Non-Small Cell Lung CancerRecruiting

Colorectal CancerRecruiting

Solid Tumors Harboring MET AmplificationRecruiting

Metastatic Pancreatic Ductal AdenocarcinomaRecruiting

Pancreatic Ductal AdenocarcinomaPhase 2/Phase 3

Active, not recruiting

Esophageal AdenocarcinomaPhase 2

Active, not recruiting

Metastatic Colorectal CancerPhase 2

Recruiting

Non-Small Cell Lung CancerPhase 1

Recruiting

Colorectal CancerPhase 3

Recruiting

Solid Tumors Harboring MET AmplificationPhase 2

Recruiting

Metastatic Pancreatic Ductal AdenocarcinomaPreclinical

Recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Telisotuzumab Adizutecan

AbbVie

Phase 3

4 2

Yervoy

Bristol-Myers Squibb

Preclinical

31 3

Gemzar

GGynecologic Oncology Group

Preclinical

72 4

PORTRAZZA

Eli Lilly

Preclinical

8 5

Lenvima

Eisai

Preclinical

6 6

Vizimpro

Pfizer

Preclinical

4 7

Ofev

Boehringer Ingelheim

Preclinical

7 8

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 9

Remeron

OOrganon and Co

Preclinical

1 10

PD-1 Inhibitor

Johnson & Johnson

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Non-Small Cell Lung Cancer

NCT05005403

Q4 2027

PreclinicalRecruiting

Non-Small Cell Lung Cancer

NCT06772623

Q2 2028

Phase 2Recruiting

Metastatic Colorectal Cancer

NCT06820463

Q3 2028

Phase 1/2Recruiting

Metastatic Colorectal Cancer

NCT06464692

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer4 trials

An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease and No Actionable Genomic Alterations

Recruiting· AbbVie logo

AbbVie·Preclinical·NCT06772623·252 enrolled

A Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Subjects With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer After Progression on a Third-Generation EGFR TKI - AndroMETa-Lung-713

Recruiting· AbbVie logo

AbbVie·Preclinical·NCT07155187·490 enrolled

A Global First-in-Human Study in NSCLC, HNSCC, and Solid Tumors With Azirkitug as a Single Agent and in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Recruiting· AbbVie logo

AbbVie·Phase 1·NCT05005403·694 enrolled

Show 1 more trial

A Phase 2/3 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Recruiting· AbbVie logo

AbbVie·Preclinical·NCT07005102·854 enrolled

Metastatic Colorectal Cancer3 trials

A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

Recruiting· AbbVie logo

AbbVie·Phase 3·NCT06614192·460 enrolled

Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Adizutecan (ABBV-400) Moves Through the Body of Adult Participants With Unresectable Locally Advanced/Metastatic Colorectal Cancer

Recruiting· AbbVie logo

AbbVie·Phase 1/2·NCT06464692·30 enrolled

A Phase 2, Open-Label, Randomized, Master Protocol Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Telisotuzumab Adizutecan in Subjects With Metastatic Colorectal Cancer

Recruiting· AbbVie logo

AbbVie·Phase 2·NCT06820463·390 enrolled

Colorectal Cancer2 trials

An Open-Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) Plus Bevacizumab to LONSURF (Trifluridine and Tipiracil) Plus Bevacizumab in Subjects With Refractory Metastatic Colorectal Cancer

Recruiting· AbbVie logo

AbbVie·Phase 3·NCT07525206·700 enrolled

A Phase 2, Randomized, Open-Label Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to the Current Standard of Care in Subjects With Post Adjuvant ctDNA Positive Colorectal Cancer and No Radiographic Evidence of Disease (NED)

Recruiting· AbbVie logo

AbbVie·Phase 2·NCT07023289·140 enrolled

ESS1 trial

Expanded Access to Telisotuzumab Adizutecan

Available· AbbVie logo

AbbVie··NCT05982873

Esophageal Adenocarcinoma1 trial

A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Recruiting· AbbVie logo

AbbVie·Phase 2·NCT06628310·180 enrolled

2 more indications

Solid Tumors Harboring MET Amplification1 trial

A Phase 2 Study to Evaluate the Safety and Efficacy of Telisotuzumab Adizutecan for the Treatment of Subjects With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification

Recruiting· AbbVie logo

AbbVie·Phase 2·NCT07196644·100 enrolled

Metastatic Pancreatic Ductal Adenocarcinoma1 trial

Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan in Combination With FOLFOX Compared to Standard of Care in Subjects With First-Line Metastatic Pancreatic Ductal Adenocarcinoma - AndroMETa-PDAC-288

Recruiting· AbbVie logo

AbbVie·Preclinical·NCT07490301·900 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Telisotuzumab Adizutecan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Telisotuzumab Adizutecan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Telisotuzumab Adizutecan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AbbVie

Telisotuzumab Adizutecan

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2027

Q2 2028

Q3 2028

Trials by Indication[1]

Non-Small Cell Lung Cancer4 trials

Metastatic Colorectal Cancer3 trials

Colorectal Cancer2 trials

ESS1 trial

Esophageal Adenocarcinoma1 trial

Solid Tumors Harboring MET Amplification1 trial

Metastatic Pancreatic Ductal Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News